The concept of neglected tropical diseases (NTDs) emerged more than a decade ago and has been recognised as a valid way to categorise diseases that aff ect the poorest individuals. Substantial progress in control and elimination has been achieved and policy momentum has been generated through continued bilateral, philanthropic, and nongovernmental development organisation (NGDO) support, and donations of drugs from pharmaceutical companies. WHO has defi ned a Roadmap to reach 2020 targets, which was endorsed by member states in a World Health Assembly Resolution in 2013. NTDs have been included within the Sustainable Development Goal targets and are a crucial component of universal health coverage, conceptualised as "leaving no one behind". WHO reported that more than 1 billion people in 88 countries have benefi ted from preventive chemotherapy in 2014. The research agenda has defi ned the need for aff ordable products (diagnostics, drugs and insecticides). However challenges such as insecurity and weak health systems continue to prevail in the poorest countries, inhibiting progress in scaling up and also in achieving Roadmap goals.
Introduction NTDs and the global heath agenda
In this Review, we will present progress since the 2010 Lancet Series on neglected tropical diseases (NTDs).
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NTDs have been defi ned as a group of infections strongly associated with poverty in tropical and subtropical environments. NTDs are diverse in biological and transmission characteristics; they predominantly infect populations in low-income and middle-income countries with limited access to health services. 5 During the past decade, the momentum to address NTDs has been driven by pledges from pharmaceutical companies to provide free medicines (all on the WHO Essential Medicines list and valued in billions of US$), NGDOs' commitments to assist implementation of programmes in endemic countries, bilateral support from the US and UK Governments, and an increase in commitment from endemic countries. 6 However, despite evidence that inter ventions to address NTDs are one of the best health invest ments, only 0·6% of offi cial development assistance for health is provided to NTDs aff ecting more than 1 billion people. This underinvestment refl ects a persistent and continuing inequity in global health fi nancing. 7 The London Declaration of 2012 8 recorded increased commitments of donated drugs for visceral leishmaniasis, lymphatic fi lariasis, and schistosomiasis, while earlier commitments to provide drugs for fascioliasis, leprosy, leish maniasis, lymphatic fi lariasis, onchocerciasis, trypanosomiasis, and soil-transmitted helminthiases at no cost to endemic countries were reinforced. In 2013, the World Health Assembly approved Resolution WHA 66.12, which defi ned strategies for NTDs with clear targets and milestones for 17 NTDs, and endorsed the WHO NTD Roadmap goals linking NTDs to universal health coverage. NTDs are addressed through fi ve strategies: preventive chemotherapy, intensifi ed disease management, vector control, veterinary public health measures for zoonotic neglected diseases, and through improved water and sanitation.
9,10
Momentum for further investment came in 2015 with the inclusion of NTDs within the health targets of the Sustainable Development Goals (SDGs) 11 when the Global Fund Board 12 agreed to support interventions that addressed co-infection and co-morbidities and the G7 Heads of State recognised NTDs as a major challenge emphasising the need to support research and interventions. 13 An agreed SDG target was to reduce the number of people accessing NTD interventions by 90% by 2030. However, the burden of NTDs is heavy on the poorest people in G20 countries (together with Nigeria) and if these countries implemented NTD programmes then a high proportion of the NTD burden could be resolved.
14 Increased investment for NTDs will improve the wellbeing of vulnerable groups, which together with improvements in water, sanitation, hygiene, and education, are appropriate links to many of the SDGs. NTDs defi ne poverty in many settings and have been described as litmus tests of progress in poverty alleviation, or are described as markers of poverty.
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NTD partnerships: evolution and expansion from disease-specifi c to a wider context
Disease-specific partnerships represent the diversity of communities involved in NTDs and have made a major contribution to scaling up of programmes. NGDO commitment was pioneered by NGDOs that supported the delivery of ivermectin for onchocerciasis control and multidrug therapy for leprosy elimination programmes. 16 Since 2010, new partnerships have emerged to coordinate and advocate for particular conditions (table) . Disease-specific alliances generate opportunities for advocacy and increased resources from non-traditional donors, and reflect the need to facilitate interaction between endemic countries, inter national organisations, non-governmental organisations, pharmaceutical donors, philanthropic foundations, and academia. 17 However, this estimate excluded deaths from rabies (55 000 deaths), snakebite (up to 94 000 deaths), cancers associated with trematode infections (60 000 deaths), and neurological NTD conditions such as neurocysticercosis-related epilepsy (60 000 deaths)-these deaths are also included in other categories. These fi gures suggest the total annual mortality from NTDs is actually around 350 000. In 2010, WHO reported that schistosomiasis mortality alone could be as high as 280 000 per year in Africa-a 20-fold diff erence from the offi cial GBD data. 19 Morbidity from permanent blindness, debilitating skin disease, disability and disfi gurement with long term psychological and social and economic consequences will elevate the total DALY burden but are not included in Global Burden of Disease metrics.
20
NTD comorbidities: HIV, epilepsy, and cancer
A possible association between HIV and urogenital schistosomiasis has been recognised. Ndeff o Mbah and colleagues 21 showed increased HIV positivity in females infected with Schistosoma haematobium. The opportunity to reduce the risk of HIV in young females (5-15 years) associated with S haematobium urogenital pathology by annual praziquantel has yet to be recognised by the HIV community, despite the need to achieve high coverage of this at-risk group irrespective of a direct link to HIV. The safety of praziquantel has been reconfi rmed during pregnancy and lactation. 22 The longstanding policy to assure coverage of young females with praziquantel treatment should be implemented by both the NTD and HIV constituencies. Neurocysticercosis infection caused by Taenia solium cysts has been associated with epilepsy and estimates suggest some 30% of global epilepsy is associated with neurocysticercosis. 23 Bladder cancer associated with S haematobium and food-borne trematode infections that cause cholioangiocarcinoma are estimated to cause 60 000 deaths annually. 24 The successful schistosomiasis control programme in Egypt has seen a rapid decline in bladder cancer during the past 2 decades. 25 Comorbidities associated with hookworm and schistosomiasis also exacerbate malaria pathology, particularly in pregnancy, which reduces birthweight and increases risk of neonatal and infant mortality. Further, the mental health comorbidity of many NTDs and the impact these conditions have on the psycho-social status of individuals and families, particularly depressive illness and anxiety of patients with NTDs as well as caregivers has only recently been highlighted as a problem with signifi cant additional burden. 26 A consensus has been reached that new drugs, insecticides, and diagnostics are required, which will off er improved and cost-eff ective therapies, vector-control tools, and diagnostics. Attempts to develop vaccines for multicellular parasites are yet to develop a product for largescale use. However, progress to address the expanding dengue threat has been made with the development of a vaccine for dengue (Dengvaxia, Sanofi Pasteur, Lyon, France). Dengvaxia has been licenced in Mexico for use in highly endemic areas, after results of safety and effi cacy studies in clinical trials showed reduced incidence of hospitalisation in vaccinated children aged 2-16 years old in three clinical trials involving 35 000 children. 27 Research to improve delivery of existing products and evaluate effi cacy of existing therapeutics will be necessary, as will exploration of combinations of products known to be eff ective. Specifi c research priorities are improved oral therapy for human African trypanosomiasis that is eff ective in both early and late stage disease; and improved chemotherapy for leishmaniases, Chagas' disease, and buruli ulcer-current therapies are not ideal owing to the duration of required treatment, mode of administration, and toxicity. A short-duration macrofi laricidal treatment to kill or permanently sterilise adult fi larial worms is still needed, because despite the effi cacy of the anti-Wolbachia antibiotic, doxycycline, the duration of treatment and eligibility criteria currently restrict its widespread use. Praziquantel has been donated for mass drug administration in school-aged children for schistosomiasis; however, it needs to be reformulated for paediatric use given that pre-school children are frequently infected. The combination of praziquantel with artesunate for treatment of both adults and juvenile forms of schistosomes might be considered. 28 Research linked to implementation of programmes and challenges that programmes face as they mature require social science involvement to improve coverage and adherence, and improved methodologies to evaluate impact and address problems identifi ed in acceptability adherence and coverage. 29 Research to understand interactions between social networks within communities could help ensure optimum understanding and uptake of drugs. 30 Increasingly complex and diverse research questions have emerged as programmes dependent on mass drug administration have progressed. Such questions relate to the duration and frequency of mass drug administration for diff erent diseases, the broad spectrum eff ectiveness of the anthelminthics used and the impact of vector control on transmission of fi lariasis. 31 
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Defi nition of research priorities
Research priorities for NTDs have been published in a series of reports by WHO and the Special Programme for Research and Training in Tropical Diseases, outlining priorities for kinetoplastid parasites (trypanosomes and leishmanias), helminth infections, zoonoses and viral infections (dengue, and other arboviruses).
Mapping disease distribution
Accurate mapping of disease distribution is a prerequisite for eff ective implementation. Onchocerciasis programmes have shown the importance of defi ning endemicity; in these programmes, levels of endemicity were defi ned by rapid epidemiological assessment and mapping. 32 The serious adverse events associated with Loa loa co-endemicity with onchocerciasis meant a rapid mapping methodology was required to defi ne areas of highest risk. 33 Similar rapid mapping using antigen detection methods are used to identify where lymphatic fi lariasis mass drug administration should be instituted. 34 The need to know the distribution of NTDs that can be controlled or eliminated by preventive chemotherapy led to the development of online resources to ensure all requisite data are available and updated. The Global Trachoma Mapping Project is an example of how mobile phone and geographic information system technologies can be used: popu lation-based prevalence surveys are done in all districts where trachoma is suspected to acquire data on burden and risk, thus enabling prioritisation of inter ventions and policy determination for implementation of the surgery, antibiotics, facial cleanliness, and environ mental improvement (SAFE) strategy. 35 Detailed mapping of foci of human African trypanosomiasis due to Trypanasoma brucei gambiense infection has defi ned areas of highest risk for active surveillance. 36 Use of remote sensing technologies to produce datasets that precisely defi ne zones of climate (rainfall indices, cloud cover), physical parameters (altitude, soil type), and ecological parameters (forest cover, vegetation type) is increasingly important, as predictors of disease ecology refl ecting drivers of transmission of vector borne infections. Defi nable physical characteristics such as soil type are associated with podoconiosis distribution. 37 The NTD global mapping tool provides an interactive means to assist the planning and implementation of preventive chemotherapy for NTDs, enabling visualisation of geographical distribution of diseases and the priority areas requiring mass drug administration where co-implementation should be initiated. The global mapping tool also complements the Global Atlas of Helminth Infections, provides information on water and sanitation, and allows progress of interventions to be tracked.
The need for alternative strategies-the operational research agenda
Some preventive chemotherapy programmes require alternative strategies to reach elimination targets, which need to be piloted and implemented. These alternative strategies include: ivermectin twice a year for fi lariasis in Africa; albendazole twice a year for lymphatic fi lariasis in L loa co-endemic areas; bednet coverage to eliminate lymphatic fi lariasis; and the use of doxycycline as a macrofi laricide or ivermectin four times per year in some areas of onchocerciasis endemicity, such as in Brazil and Venezuela. 31, 38 Thomsen and colleagues 39 examined a triple combination of diethylcarbamazine, albendazole, and ivermectin for fi lariasis and showed that microfi laria levels remain suppressed for a 24 month period thus providing an opportunity to reduce the frequency of mass drug administration in areas where onchocerciasis is not co-endemic. Additionally, to reduce the problem of the limited eff ect of albendazole on trichuris infections, ivermectin should be considered; however, ivermectin is not donated for trichuris infections or for scabies. Because extensive insecticide resistance exists in Africa, the value of bednets to eliminate Wuchereria bancrofti transmission needs to be reassessed.
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Cochrane systematic reviews: the deworming debate
In 2015, the Cochrane Collaboration challenged the benefi ts of deworming for the control of soil-transmitted helminthiases after their analysis 41 of randomised controlled trials (RCTs). This fi nding provoked robust debate 42 about whether RCTs are an appropriate way to measure the nutritional and educational benefi ts of preventive anthelminthic chemotherapy. Most RCTs do not take into account that recovery from nutritional defi cits is a process that takes much longer than 1 year, especially if the quality and quantity of the nutrients assumed in the diet are limited.
Furthermore, a signifi cant proportion of individuals treated with preventive chemotherapy are uninfected but are nevertheless treated for logistical reasons and thus no nutritional benefi ts are expected to accrue in this group. RCTs normally calculate the mean benefi t of preventive chemotherapy on the entire treated group but the true benefi ts are obtained only by those infected and are therefore greatly diluted.
Additionally, diff erent worm species have diff erent patho logical eff ects-hookworm causes anaemia, ascariasis retards growth 43 -hence when the results of preventive chemotherapy are evaluated it is important to recognise which species of soil-transmitted helminthiases are removed. For example, an improvement in haemo globin levels should not be expected if hookworms are not the prevalent species in the population treated. On the basis of the evidence from all studies including RCTs, WHO issued a consensus statement reiterating the justifi cation of the present policy of preventive chemo therapy. 42 Provision of deworming to infected populations refl ects equity and ethical aspects and the intervention is recognised to reinforce the trust in the health and education service, aspects that the Cochrane systematic review of RCTs is unable to evaluate. 
Progress towards Roadmap goals Progress on specifi c diseases
Substantial progress towards WHO Roadmap goals and regional targets has been achieved since 2010 (table) . The Uniting to Combat NTDs initiative tracks progress on ten NTDs towards the agreed targets against a scorecard that is published annually.
Dracunculiasis (Guinea worm disease)
Since the introduction of the Guinea Worm Eradication Programme in 1986, 16 countries have been certifi ed free of Guinea Worm transmission, including 6 countries since 2010 (Burkina Faso, Côte d'Ivoire, Ghana, Niger, Nigeria, and Togo). However, four countries remain endemic-Chad, Ethiopia, Mali, and South Sudan-who reported only 22 cases in 2015 compared with 126 cases in 2014. 44 Each of these endemic countries pose diff erent challenges if transmission cessation is to be confi rmed. A possible cycle of transmission that involves dogs, fi sh, and amphibians as paratenic hosts was discovered in Chad, meaning a change in approach could be required because 503 dog infections were recorded in Chad in 2015; from January, to June, 2016, 498 dogs have been reported infected and four human cases have been identifi ed in Chad. Human cases were also reported in South Sudan and Ethiopia in June, 2016. 44, 45 In Mali, access to endemic areas is curtailed due to insecurity. In South Sudan, strong progress has been made to reduce the numbers of infected villages but problems of access, population movement, cattle camps, and insecurity pose end-game challenges.
Human trypanosomiases
Achievement of the target to reduce the number of chronic human African trypansomiasis cases to between 2000-3000 cases per year by 2015 is close: WHO reported 3796 cases in 2014 and less than 3000 in 2015. This fi gure was the lowest reported incidence for 75 years and was achieved by active surveillance of defi ned high-risk foci and donation of products for chronic human African trypansomiasis therapy (pentamidine and nifurtimox-efl ornithine). 46 The availability of tiny insecticide impregnated targets for glossina control, 47 new diagnostic tests, and the prospect of an oral therapy to treat both phases of the diseasefexnidazole, which is now in phase 2 and 3 trials calls for optimism.
Chemotherapy for Chagas' disease remains problematic; less than 1% of patients have access to benznidazole. Despite an impact on parasite serological parameters, a randomised trial of benznidazole did not signifi cantly reduce levels of cardiac clinical deterioration through 5 years of follow-up. A substantial decrease in the global disease burden has been achieved; the number of leprosy cases has reduced from 5·2 million in 1985, to 180 618 cases at the end of 2013, which has led to the suggestion that the public health problem has been eliminated-defi ned by WHO as a prevalence of less than 1 case per 10 000. However, although the problem of leprosy has been reduced by multidrug therapy, pockets of high endemicity remain in several countries, including India, Brazil, and Indonesia, therefore this ancient and stigmatising disease should remain a priority.
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Lymphatic fi lariasis
In 2014, 73 countries remained endemic for lymphatic fi lariasis; 18 countries are now entering the surveillance phase but 11 countries have not yet commenced mass drug administration programmes. Some 23 countries have only implemented limited mass drug administration and have not reached 100% geographical coverage. Countries that have not achieved complete coverage will not be able to reach the 2020 target of elimination. However, 18 countries have moved into a surveillance phase following transmission assessment surveys, an evaluation which suggests transmission has been arrested. 50 However, The Gambia appears to have eliminated transmission, without the introduction of mass drug administration, with long-term use of impregnated bednets for malaria control. 51 A 2014 estimate of the impact of mass drug administration during the past 13 years suggests more than 96·71 million cases of lymphatic fi lariasis were prevented or cured; yet 36 million cases of hydrocoele and lymphoedema remain. 52 The economic benefi ts estimated to have accrued during the fi rst 8 years of the programme exceed $24 billion. In 2014, 559 million people were treated for lymphatic fi lariasis and the cumulative number of treatments reported was 5·62 billion to more than 1 billion individuals. 53 The fi lariasis test strip, which is based on the immunechromatographic test, has been introduced as an improved method for use in mapping and evaluation. 53 This test will be used for transmission assessment surveys to determine the impact of mass drug administration and allow for decision making with regard to cessation or to evaluate any recrudescence. Lymphatic fi lariasis accounts for at least 2·8 million disability-adjusted life-years; 17 this fi gure does not include the substantial comorbidity of mental illness commonly experienced by patients and their caregiv ers. 20 For WHO's Global Programme to Eliminate Lymphatic Filariasis to succeed, 100% geographical coverage of both mass drug administration and patient care is necessary and could be achieved through the implementation of morbidity management and surgery. 50 For Uniting to Combat NTDs see http://unitingtocombat ntds.org
Onchocerciasis
Three countries have been verifi ed as free of transmission of Onchocerca volvulus: Colombia, Ecuador, and Mexico. Guatemala has submitted a dossier that indicates that transmission has stopped in all the previous endemic foci, while the northern focus in Venezuela is under postcontrol surveillance. However, the cross-border focus straddling Brazil and Venezuela exemplifi es challenges of remote areas; migratory Yanomami groups who require treatment characterise the diffi culties of sustaining ivermectin distribution four times per year. Some infected individuals who remain positive have been hospitalised for treatment with the macrofi laricide doxycycline. 54 Closure of the African Programme for Onchocerciasis Control at the end of 2015 and the creation of the Expanded Special Project for the Elimination of NTDs in Africa for the control of other preventive chemotherapytargeted NTDs will transfer the responsibility to provide technical support to country programmes to the WHO Regional Offi ce for Africa. The African Programme for Onchocerciasis Control delivered more than 1 billion treatments between 1997 and 2014 in 19 countries, built capacity through training or retraining of more than 148 000 health workers and 1·46 million community directed distributors, facilitated use of community structures for other health programmes, and empowered more than 190 000 communities to direct their own ivermectin treatment schedules. 55 The African Programme for Onchocerciasis Control made epidemiological progress towards nationwide elimination in Burundi, Chad, Guinea Bissau, Kenya, Malawi, Mali, Niger, and Senegal. Focal elimination in six countries (Cameroon, Ethiopia, Nigeria, Sudan, Tanzania, and Uganda) was achieved, but in Cameroon there are diffi culties in high transmission zones that are co-endemic with L loa. In such zones, coverage and adherence are inadequate to satisfy the expectation that transmission can be arrested without implementation of additional strategies.
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Scabies
Scabies is caused by the ecto-parasitic mite Sarcoptes scabiei and is highly susceptible to ivermectin, which is used in onchocerciasis and lymphatic fi lariasis programmes. The results of a study 56 in Fiji showed effi cacy of ivermectin for scabies compared with standard treatments of topical permethrin cream. The lack of data on the impact of ivermectin on scabies after nearly 3 decades of use in mass drug administration programmes is a major defi cit, representing a missed opportunity.
Schistosomiasis
The World Health Assembly resolution of 2012 (WHA 65.21) 57 called for the elimination of schistosomiasis and reinforced the importance of regular treatment of at least 75% of school age children in areas at risk of both schistosomiasis and soil-transmitted helminthiasis as stated in a previous resolution (WHA 54.19) . 58 Schistosomiasis programmes will now benefi t from the increased donation of praziquantel, because from 2016, 250 million tablets equivalent to 100 million treatments will be available. The number of school-age children treated in 2014 was 49·2 million, equivalent to 34.6% of global coverage for this age group. In spite of this signifi cant progress, scale-up remains slow in the highest burden countries where 70% of the burden occurs. If the elimination goals for schistosomiasis are to be met, endemic countries should defi ne high priority intervention areas, access the available donated drug, implement health education messages to emphasise the importance of safe water and sanitation provision in reduction of transmission, and recognise the importance of pre-school age children and their need for treatment if possible with a paediatric formulation of praziquantel. 59 The association between HIV and urogenital schistosomiasis requires resolution with strong policy enforcement through the regular treatment of school girls, women of childbearing age, and throughout pregnancy and lactation as recommended by WHO and the original manufacturers of praziquantel. 
Soil-transmitted helminthiases
Between 2008 and 2013, the number of children treated for soil-transmitted helminthiases doubled. WHO reported that 440 million pre-school and school-age children were treated in 2014 with anthelminthics (albendazole and mebendazole)-rates of coverage have increased since 2008 and a global coverage of 44-51% has been achieved.
6, 60 The fi gures for treatment of soiltransmitted helminthiases do not include individuals receiving anthelminthics via fi lariasis and onchocerciasis programmes that treat adults as well as younger age groups. 31 The need to treat adults is recognised, if a permanent reduction in transmission is to be achieved, 61 as well as the importance of the role of the water, sanitation, and hygiene sector to sustain the gains regular deworming can provide.
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Trachoma
The SAFE strategy for the elimination of trachoma with its four components-surgery, antibiotics, face washing, and environment-shows the multiple approaches required if public health goals are to be achieved. 46 The Global Trachoma Mapping Project provided detailed information for implementation of mass drug administration using azithromycin, identifi ed where the burden of trichiasis is highest for prioritisation of surgery, and identifi ed where implementation of the face washing and environment components of the SAFE strategy will pose the greatest challenge. 36 The implementation of mass drug administration in all endemic districts at 80% coverage for 3-5 years, depending on prevalence of active trachoma, will pose a has emphasised the benefi t of improved trichiasis surgery technique in reducing recurrence of trachoma.
Yaws
Yaws (Treponema pallidum pertenue) is a disabling skin condition that has been identifi ed as a potential eradication target on the basis of oral azithromycin effi cacy. WHO developed the Morges Strategy for Yaws Eradication by 2020; 64 the strategy will involve mass drug administration of single dose azithromycin to entire endemic communities, supported by surveillance until clinical cases are no longer detected, and by treatment of all active cases and their contacts. Pilot interventions have been initiated in several countries: in Nsukka, Nigeria, mass drug administration with oral azithromycin interrupted transmission within 6-12 months. In India, after a 20 year campaign using penicillin injection followed by serosurveillance of children for treponemal antibodies, WHO reported 65 that yaws was no longer present in India and declared its eradication (technically elimination).
Implementation strategies requiring collaboration with other sectors Vector control
Vector control has been a major component of NTD programmes over many decades. Many NTDs such as lymphatic fi lariasis, visceral leishmaniasis, onchocerciasis, and Chagas' disease have benefi ted from vector control. 66 Additionally, new approaches to the control of human African sleeping sickness using tiny target technology 47 or selective spraying of cattle to control the acute zoonotic form of disease have been shown to be eff ective interventions but require implementation at scale. 67 Development of novel tools and methods to curb the spread of (day-biting and outdoor-biting) Aedes aegypti mosquitoes that transmit dengue 68 and Chikungunya 69 is a high priority, reinforced by the emergence of Zika virus. Development of novel vector control methods will require substantially increased investment if they are to be implemented. 6 Increasing levels of resistance to present pyrethoid-based insecticides threaten the progress of the lymphatic fi lariasis elimination programme in Africa. 40 Global warming, climate change, unplanned urbanisation, and global travel of people and goods, will have an impact beyond the traditional populations associated with NTDs. The establishment of schisto somiasis in Corsica exemplifi es these threats; snail populations have been found in Corsica that are susceptible to infection with a parasite strain from Africa, a hybrid of S haematobium and Schistosoma bovis, therefore these strains could become established in southern Europe. 70 
Neglected zoonotic diseases: the One Health concept
Neglected zoonotic diseases occur in many settings, caused by diverse groups of organisms, hence generalisations about approaches to their control is diffi cult. However, progress has been made to defi ne strategies for control of specifi c diseases, which require an approach that goes beyond the health sector. 71 The vision for One Health is a culture change that recognises the importance of the link between humans, animals, and ecosystems, providing added value by translation of the One Health approach into zoonotic disease control. Successful application of One Health strategies are the use of dog vaccination in the control of human rabies in Latin America, KwaZulu-Natal, the Philippines, and Bali, 72 and the control of the acute form of human sleeping sickness, Trypansoma brucei rhodesiense, in south east Uganda. In Uganda, 67 chemotherapy of the cattle reservoir, together with vector control by spraying of cattle to selectively kill the tsetse fl y Glossina fuscipes, has been shown to eff ectively reduce the incidence of sleeping sickness cases. 67 The One Health approach can also be applied to the control of cysticercosis and echinococcosis, globally distributed cestode infections, in which interventions focused on animal reservoirs (pigs and dogs) are essential components of interventions to reduce human prevalence allied to behaviour change and curative therapy. 73, 74 Water, sanitation, and hygiene Sustained control and elimination of soil-transmitted helminthiases and schistosomiasis, require not only chemotherapy, but also access to clean and safe water together with appropriate waste disposal and behaviour changes to reduce transmission. However, provision of clean and safe water in the more remote areas where NTDs and other waterborne infections are most prevalent poses a substantial challenge and the involvement of other sectors is required. Engagement of the water, sanitation, and hygiene sector and the inclusion of NTDs within this framework, refl ects a holistic policy approach within the SDG goals.
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Place of NTDs in the global health context towards 2030
During the past decade, NTDs have attracted increased attention and investment. Availability of drugs is no longer a barrier to achievement of universal health coverage for most NTDs yet they remain a chronic pandemic in the poorest sectors of society in endemic countries who now have access to donated drugs. Further progress will be driven by commitment of countries to contribute to the relatively small costs of deliveryestimated at 1-3% of national health budgets-to ensure access to donated products with a calculated annual value of $2-3 billion. In 2015, 1·1 billion people received preventive chemo therapy, representing a public health success, and 140 million children were dewormed in a single day in February, 2016, in India. 75 However, progress towards achievement of the 2020 WHO Roadmap targets has been patchy. The resources allocated to NTDs are not yet adequate to address the totality of the problem. The Contributors DHM wrote the fi rst draft and took the lead role in development of the paper; LS and DE contributed to further development of the content and structure of the paper, in particular the policy elements and editing, and agreed to the fi nal version. estimated requirements to achieve Roadmap goals are double the current $300 million annual funding provided. However if vector control is included the estimated amount required would be ten times that amount. 6 The challenge is to persuade endemic countries to invest national resources to develop robust and dependable health delivery systems to ensure the gains from NTD control or elimination are translated into long-term human development gains.
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NTDs are tracers of equity in progress toward other SDGs and targets, 15 including universal health coverage (target 3.8), access to safe water (target 6.1), and sanitation (target 6.2). NTD endemic populations are the least likely to have access to such services, hence use of NTDs as an indicator of progress is a logical step to justify these diseases in the SDG targets. Other SDG goals upon which NTD interventions and partnerships are relevant are education (target 4), gender equality (target 5), decent work and economic growth (target 8), reduced inequalities (target 10), sustainable cities and communities (target 11), climate action (target 13), and partnership for the goals (target 17). The most recent WHO and World Bank report 76 on monitoring of universal health coverage is explicit that "monitoring preventive chemotherapy remains key to ensuring that the diseases of the least well-off are being prioritised from the very beginning of the path to UHC".
However, additional challenges exist with respect to implementation as well as the need for a new generation of products: countries have limited human resources; some populations are diffi cult to access; civil unrest and confl ict impede implementation; 77 drug resistance and insecticide resistance could develop; and environmental change impacts on the ecology and behaviour of vectors. 40 Additionally, the value of quantitative and mathematical modelling approaches to inform policy decisions for a group of NTDs has been emphasised through the work of the NTD Modelling Consortium. 78 A 2016 study 79 on health gains from NTD programmes has estimated that 175 million DALYs have been averted in the 15 years of the lymphatic fi lariasis programme,while if targets are met for nine NTDs 600 million DALYs would be averted, which can be extrapolated to 2030 largely due to the decline in morbidity of NTDs treated by preventive chemotherapy. 80 However, this fi gure does not estimate for gains in subtle morbidities through improved cognitive development and mental health and only nine NTDs were used in the calculation. This suggests that overall gains in DALYs from all NTD programmes would be substantially greater than the 600 million DALY fi gure.
The stated commitments of donors should be translated into resources to redress the inequities of fi nancing, from which NTD programmes presently suff er, to give the poor what they deserve: access to free, high quality eff ective products as they continue to be exposed to an avoidable chronic pandemic which claimed at least ten-times more lives than the Ebola epidemic in a single year.
